Table 1.
Patient characteristics by BDX008 classification for all patients and by BRAF status
| All patients (N = 71) | BRAF WT (N = 39) | BRAF MUT (N = 25) | ||||
|---|---|---|---|---|---|---|
| BDX008+ (N = 30) | BDX008- (N = 41) | BDX008+ (N = 15) | BDX008- (N = 24) | BDX008+ (N = 12) | BDX008- (N = 13) | |
| Age | ||||||
| Median (Range) | 59 (28–86) | 66 (32–80) | 59 (34–86) | 61 (44–80) | 52 (29–69) | 67 (32–78) |
| Gender, n (%) | ||||||
| Female | 16 (53) | 19 (46) | 8 (53) | 10 (42) | 7 (58) | 7 (54) |
| Male | 14 (47) | 22 (54) | 7 (47) | 14 (58) | 5 (42) | 6 (46) |
| BRAF Status, n (%) | ||||||
| Mutation | 12 (40) | 13 (32) | 0 (0) | 0 (0) | 12 (100) | 13 (100) |
| Wild Type | 15 (50) | 24 (59) | 15(100) | 24(100) | 0 (0) | 0 (0) |
| NA | 3 (10) | 4 (10) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Line of Therapy with anti-PD-1, n (%) | ||||||
| 1st | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 2nd | 4(13) | 13 (32) | 3 (20) | 9 (38) | 0 (0) | 3 (23) |
| 3rd | 17(57) | 16 (39) | 11 (73) | 11 (46) | 5 (42) | 3 (23) |
| 4th | 4 (13) | 10 (24) | 1 (7) | 4 (17) | 3 (25) | 6 (46) |
| 5th and higher | 4 (13) | 2 (5) | 0 (0) | 0 (0) | 4 (33) | 1(8) |
| Targeted therapy, n (%) | ||||||
| No | 18 (60) | 28 (68) | 14 (93) | 22 (92) | 2 (15) | 1 (8) |
| Yes | 12 (40) | 13 (32) | 1 (7) | 2 (8) | 11 (85) | 11 (92) |
| Anti-PD-1 agent, n (%) | ||||||
| Nivolumab | 9 (30) | 15 (37) | 6 (40) | 10 (42) | 1 (8) | 4 (31) |
| Pembrolizumab | 21 (70) | 26 (62) | 9 (60) | 14 (58) | 11 (92) | 9 (69) |
| NLR, n (%) | ||||||
| <5 | 25 (83) | 19 (46) | 14 (93) | 12 (50) | 8 (67) | 5 (38) |
| ≥5 | 5 (17) | 22 (54) | 1 (7) | 12 (50) | 4 (33) | 8 (62) |
| LDH | ||||||
| Median (in IU/l) | 402 | 617 | 379 | 525 | 416 | 728 |
| NA, n (%) | 5 (17) | 2 (5) | 3 (20) | 2 (8) | 2 (17) | 0 (0) |
| <2ULNa, n (%) | 22 (73) | 21 (51) | 12 (80) | 15 (63) | 7 (58) | 5 (38) |
| 2ULNa, n (%) | 3 (10) | 18 (44) | 0 (0) | 7 (29) | 3 (25) | 8 (62) |
| Melanoma Type, n (%) | ||||||
| cutaneous | 22 (73) | 24 (59) | 11 (73) | 14 (58) | 10 (83) | 9 (69) |
| mucosal | 2 (7) | 1 (2) | 2 (13) | 1 (4) | 0 (0) | 0 (0) |
| SPI | 2 (7) | 2 (5) | 1 (7) | 1 (4) | 1 (8) | 0 (0) |
| uveal | 2 (7) | 4 (10) | 0 (0) | 3 (13) | 0 (0) | 0 (0) |
| NA | 2 (7) | 10 (24) | 1 (7) | 5 (21) | 1 (8) | 4 (31) |
aULN upper limit of normal (333 IU/l)